Recently the World Malaria report reviewed 20 years of malaria response. Since 2000, 7.6 million lives have been saved globally and 1.5 billion Malaria cases averted. In these last two decades European Vaccine Initiative (EVI) has supported a diverse and extensive portfolio of Malaria Vaccine candidates. The most advanced Malaria vaccine candidate, supported by EVI, is R21/Matrix M, a pre-erythrocytic vaccine candidate that is currently undergoing phase II clinical trial and